Skip to main content

Table 2 Comparison of mean delta Ct values for each of the 16 genes in the 16 gene signature in discovery dataset patients pre-treatment and post-treatment. Expression of the genes in patients who developed grade 0–1 diarrhea are compared to patients who developed grade 2–4 diarrhea

From: A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab

Discovery Dataset
  Gene Expression Delta Ct Values Pre-Treatment Means Gene Expression Delta Ct Values Post-Treatment Means
  Grade 0–1 Diarrhea Pre Treatment N = 129 Grade 2–4 Diarrhea Pre Treatment N = 21 Pre-Treatment Difference Grade 0–1 Diarrhea Post Treatment N = 129 Grade 2–4 Diarrhea Post Treatment N = 21 Post Treatment Difference Post Treatment Difference p value
Predictor Gene Name
 CCR3 16.71 16.98 0.27 16.28 17.40 1.12 0.0001
 CCL3 20.60 20.90 0.30 20.47 21.00 0.53 0.007
 IL8 22.14 21.84 −0.30 22.47 23.13 0.65 0.014
 IL5 23.08 23.20 0.12 22.74 23.42 0.67 0.017
 GADD45A 19.86 20.05 0.19 19.62 19.28 −0.34 0.031
 PTGS2 17.40 17.49 0.09 17.43 17.76 0.33 0.037
Enhancer Variable Gene Name
 MMP9 14.29 14.41 0.11 14.20 13.69 −0.52 0.078
 CARD12 17.63 17.73 0.09 17.54 17.25 −0.29 0.096
 SOCS3 18.31 18.42 0.11 18.11 17.78 −0.33 0.114
 F5 17.98 18.04 0.06 17.69 17.40 −0.29 0.120
 TLR9 18.14 18.11 −0.03 18.01 18.14 0.14 0.270
 FAM210B 15.21 15.32 0.11 15.35 15.58 0.23 0.325
 IL18BP 17.55 17.42 −0.13 17.32 17.46 0.14 0.355
 UBE2C 21.23 21.31 0.08 20.31 20.17 −0.14 0.358
 CXCL1 19.80 19.87 0.07 19.95 20.09 0.14 0.381
 IL2RA 19.04 18.84 −0.20 18.44 18.57 0.12 0.486